Clinical Trials

Inclusion Criteria

• Age range: 18 - 75 years
• Gender: Male of female
• Target disease or condition: Lung transplant recipients with treatment refractory moderate to severe o-CLAD. Patient must have diagnosis of treatment refractory o-CLAD Subject must have failed a standard immunosuppression regimen for lung transplant recipients and authorization for use of and disclosure of PHI.

Exclusion Criteria

• Patients with clinically significant illness with manifestations of significant organ dysfunction which in the judgment of the PI or co-investigator would render the study subject unlikely to tolerate the MSC infusion or complete the study.
• Patient should not have cancer not deemed to be in remission (superficial skin cancer shall not be deemed an exclusion criteria).
• Evidence or history of autoimmune disorders independent of o-CLAD.
• Pregnant or breast-feeding.
• Positive screening for HIV Hepatitis B and Hepatitis C.
• Evidence of liver dysfunction; Liver profile showing alkaline phosphatase higher than 345 u/L, total bilirubin greater than 1.65 mg/dL, ALT greater than 275 units/L and AST great than 240 units/L.
• Evidence of significant cardiac dysfunction.
• Septicemia with high fever and hemodynamic instability.
• History of CMV pneumonitis.
• Patients who received any experimental therapy (drug or biologic) for any indication within 12 months of the study enrollment.